3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
NETWORK
1
Study Type
Interventional
1
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
12
Prostatic Neoplasms
9
Neoplasms
9
Lung Neoplasms
6
Endometrial Neoplasms
6
Breast Neoplasms
6
Stomach Neoplasms
4
Oropharyngeal Neoplasms
4
Melanoma
4
Colorectal Neoplasms
4
Pathologic Complete Response
3
Pancreatic Neoplasms
3
Neoplasm Metastasis
3
Mouth Neoplasms
3
Leukemia, Myeloid, Acute
3
Squamous Cell Carcinoma of Head and Neck
2
Sarcoma
2
Rectal Neoplasms
2
Meningioma
2
Lymphoma, Large B-Cell, Diffuse
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Leiomyoma
2
Carcinoma, Intraductal, Noninfiltrating
2
Carcinoma, Hepatocellular
2
Carcinoma, Basal Cell
2
Vaginal Neoplasms
1
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Triple Negative Breast Neoplasms
1
Trauma, Nervous System
1
Interventions
Specimen Handling
3
Blood Specimen Collection
3
Surveys and Questionnaires
2
Standard of Care
2
Practice Guidelines as Topic
2
COVID-19 Vaccines
2
COH04S1 COVID-19 vaccine
2
2019-nCoV Vaccine mRNA-1273
2
sotrovimab
1
ciclesonide
1
Therapeutics
1
Telemedicine
1
Sodium Chloride
1
Patient Reported Outcome Measures
1
Observation
1
Nutritional Status
1
Niclosamide
1
IMM-101
1
Exercise Therapy
1
Exercise
1
Educational Status
1
Diagnostic Tests, Routine
1
Data Collection
1
CVnCoV COVID-19 vaccine
1
BNT162 Vaccine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
COVID-19
×
Observation
×
1 year
×
Clear all
NCT04442048
2025-12-30
COV-IMMUNO
Canadian Cancer Trials Group
Phase 3
Completed
195 enrolled